Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-09-11 16:05:18 ET · period of report 2026-09-10 · accession 0001506916-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-11 16:05 | 2026-09-10 | TVTX | Meckler Jeffrey A | Dir | M - OptEx | $21.98 | +20.0K | 111.5K | +22% | +$439.6K |
| DMT | 2026-09-11 16:05 | 2026-09-10 | TVTX | Meckler Jeffrey A | Dir | S - Sale+OE | $67.31 | -20.0K | 91.5K | -18% | -$1.35M |
| DMT | 2026-09-11 16:05 | 2026-09-10 | TVTX | Meckler Jeffrey A | Dir | M - OptEx | $0.00 | -20.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-10 | M | A | 10,000 | $17.44 | 101,500 | D | — | — | |
| 2 | Common | Common Stock | 2026-09-10 | M | A | 10,000 | $26.52 | 111,500 | D | — | — | |
| 3 | Common | Common Stock | 2026-09-10 | S | D | 1,700 | $65.39 | 109,800 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. (F2) The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 4 | Common | Common Stock | 2026-09-10 | S | D | 1,200 | $66.15 | 108,600 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. (F3) The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Common | Common Stock | 2026-09-10 | S | D | 14,000 | $67.46 | 94,600 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. (F4) The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 6 | Common | Common Stock | 2026-09-10 | S | D | 3,100 | $68.09 | 91,500 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. (F5) The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 7 | Derivative | Stock option (right to buy) | 2026-09-10 | M | D | 10,000 | $0.00 | 0 | D | $17.44 · — to 2027-05-17 | 10,000 Common Stock | (F6) The stock option is fully vested and exercisable. |
| 8 | Derivative | Stock option (right to buy) | 2026-09-10 | M | D | 10,000 | $0.00 | 0 | D | $26.52 · — to 2028-05-09 | 10,000 Common Stock | (F6) The stock option is fully vested and exercisable. |